Diabefarm MV - Instructions For Use, Tablets 30 Mg, Price, Reviews

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Diabetharm MV

Diabefarm MV: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Use in the elderly
14. 14. Drug interactions
15. 15. Analogs
16. 16. Terms and conditions of storage
17. 17. Terms of dispensing from pharmacies
18. 18. Reviews
19. 19. Price in pharmacies

Latin name: Diabefarm MR

ATX code: A10BB09

Active ingredient: gliclazide (Gliclazide)

Producer: LLC Pharmacor Production (Russia)

Description and photo update: 2019-11-07

Prices in pharmacies: from 95 rubles.

Buy

Diabetharm MV is an oral hypoglycemic drug.

Release form and composition

Dosage forms of Diabetharma MV:

• modified-release tablets: flat-cylindrical, white with a grayish-yellowish tinge, with a chamfer and a cross-shaped line (in a carton box 1 bottle of 60 tablets or 3 or 6 blisters of 10 tablets);
• prolonged-release tablets: oval biconvex, almost white or white with a grayish-yellowish tinge, on both sides with risks (in blister strip packs: in a cardboard box 5 packs of 6 pcs., or 3, 6, 9 packs of 10 pcs., or 5, 10 packs of 12 pcs., or 2, 4, 6, 8 packs of 15 pcs.).

Each pack also contains instructions for using Diabepharm MV.

Composition of 1 tablet:

• active substance: gliclazide - 30 or 60 mg;
• auxiliary components: magnesium stearate, hypromellose, colloidal silicon dioxide, microcrystalline cellulose.

Pharmacological properties

Pharmacodynamics

Gliclazide is the active substance of Diabepharm MV, belongs to the number of oral hypoglycemic drugs, II generation sulfonylurea derivatives.

The main effects of gliclazide:

• stimulation of insulin secretion by β-cells of the pancreas;
• increased insulin-secretory effects of glucose;
• increased sensitivity of peripheral tissues to insulin;
• stimulation of the activity of intracellular enzymes - muscle glycogen synthetase;
• decrease in the interval from the moment of eating to the beginning of insulin secretion;
• restoration of the early peak of insulin secretion (this is the difference between gliclazide and other sulfonylurea derivatives, which have an effect mainly during the second stage of secretion);
• decrease in postprandial increase in glucose levels.

In addition to the effect on carbohydrate metabolism, gliclazide improves microcirculation: it reduces platelet aggregation and adhesion, prevents the appearance of atherosclerosis and microthrombosis, normalizes vascular permeability, and restores physiological parietal fibrinolysis.

Also, the effect of the substance is aimed at reducing the sensitivity of vascular receptors to adrenaline and slowing down the onset of diabetic retinopathy at the non-proliferative stage.

Against the background of long-term use of Diabepharm MV in patients with diabetic nephropathy, a significant decrease in the severity of proteinuria occurs. It has an effect mainly on the early peak of insulin secretion, therefore it does not lead to an increase in body weight and does not cause hyperinsulinemia; contributes to weight loss in obese patients with an appropriate diet.

Pharmacokinetics

After oral administration, gliclazide is almost completely absorbed from the gastrointestinal tract. The plasma concentration of the active substance increases gradually, reaching its maximum in 6–12 hours. Food intake has no effect on the absorption of the drug. The connection with plasma proteins is approximately 95%.

Metabolism occurs in the liver, resulting in the formation of inactive metabolites. The half-life is about 16 hours. Excretion is carried out mainly by the kidneys in the form of metabolites, approximately 1% of the dose is excreted unchanged.

In elderly patients, no significant clinical changes in the pharmacokinetics of gliclazide are observed. The daily intake of a single dose of the drug provides an effective therapeutic plasma concentration of the substance within 24 hours due to the characteristics of the dosage form.

Indications for use

Diabefarm MB tablets are prescribed for the treatment of type 2 diabetes mellitus in addition to diet therapy and moderate exercise if they are ineffective.

Contraindications

Absolute:

• type 1 diabetes mellitus;
• severe hepatic and / or renal failure;
• diabetic ketoacidosis, diabetic coma, diabetic precoma, hyperosmolar coma;
• paresis of the stomach, intestinal obstruction;
• extensive burns, major surgical interventions, trauma and other conditions that require insulin therapy;
• leukopenia;
• conditions occurring with impaired absorption of food, the development of hypoglycemia (diseases of infectious etiology);
• pregnancy and lactation;
• age up to 18 years;
• individual intolerance to the components of the drug.

Relative (Diabefarm MB tablets should be used under closer supervision):

• febrile syndrome;
• diseases of the thyroid gland, proceeding with a violation of its function;
• alcoholism;
• elderly age.

Diabefarm MV, instructions for use: method and dosage

Diabefarm MV is taken orally, in the morning during breakfast, once a day. It is recommended to swallow the tablet or half of the tablet (if necessary, dividing the tablet with a dosage of 60 mg) whole, without crushing or chewing.

The dose is selected individually, it depends on the clinical manifestations of the disease, as well as the level of glucose on an empty stomach and 2 hours after eating.

The recommended initial daily dose (including for elderly patients) is 30 mg, if necessary, the dose can be further increased with a break of at least 14 days. The maximum dose is 120 mg per day.

Patients taking Diabetharm can replace it with Diabetharm CF.

The drug can be used in combination with other hypoglycemic agents: insulin, biguanides or α-glucosidase inhibitors.

Side effects

The use of Diabepharm MV against the background of an inadequate diet or in violation of the dosage regimen can lead to the development of hypoglycemia. This disorder manifests itself as headache, fatigue, aggressiveness, severe weakness, hunger, sweating, anxiety, inattention, irritability, inability to concentrate, delayed reaction, depression, visual impairment, aphasia, tremors, feelings of helplessness, sensory disorders, loss of self-control, dizziness, delirium, hypersomnia, convulsions, loss of consciousness, bradycardia, shallow breathing.

Other possible side effects:

• digestive organs: dyspepsia (manifested in the form of nausea, diarrhea, a feeling of heaviness in the epigastrium), anorexia (the severity of this disorder decreases when the drug is taken with meals), hepatic dysfunction (increased activity of hepatic transaminases, cholestatic jaundice);
• hematopoiesis: thrombocytopenia, anemia, leukopenia;
• allergic reactions: maculopapular rash, urticaria, itching.

Overdose

The main symptoms: hypoglycemia up to hypoglycemic coma.

Therapy: intake of easily digestible carbohydrates (sugar); if the patient has lost consciousness, intravenous administration of a 40% glucose solution (dextrose), intramuscular administration of 1-2 mg of glucagon is indicated. After consciousness is restored, the patient should be given food rich in easily digestible carbohydrates in order to avoid the recurrence of hypoglycemia.

special instructions

Diabetharm CF should be taken in combination with a low-calorie diet that is low in carbohydrates. Regular fasting and post-meal blood glucose monitoring is required.

In the case of diabetes decompensation or in the case of surgical interventions, the possibility of using insulin preparations should be considered.

With fasting, taking nonsteroidal anti-inflammatory drugs, or ethanol, the risk of hypoglycemia increases.

In case of emotional or physical stress, a change in diet, the dose of the drug must be adjusted.

Weakened patients and patients with pituitary-adrenal insufficiency, as well as elderly people who do not receive a balanced diet, are especially sensitive to the action of Diabetharm MV.

Influence on the ability to drive vehicles and complex mechanisms

At the beginning of therapy and when selecting a dose, patients prone to the development of hypoglycemia are advised to abandon driving vehicles and activities that require quick psychomotor reactions and increased attention.

Application during pregnancy and lactation

Diabefarm MB 30 mg and 60 mg tablets are not prescribed during pregnancy / lactation.

Pediatric use

The drug is not prescribed for patients under 18 years of age.

With impaired renal function

Diabetharm MV is contraindicated in patients with severe renal failure.

For violations of liver function

Diabetharm MV is contraindicated in patients with severe hepatic insufficiency.

Use in the elderly

In elderly patients, therapy should be carried out under close medical supervision.

Drug interactions

Hypoglycemic action Diabefarma CF reinforce the following drugs: inhibitors of angiotensin converting enzyme inhibitors (enalapril, captopril), blockers of H ₂-histamine receptors (cimetidine), anabolic steroids, indirect coumarin anticoagulants, monoamine oxidase inhibitors, β-blockers, antifungal agents (fluconazole, miconazole), tetracycline, non-steroidal anti-inflammatory drugs, phydometaphenol (clofibrate, bezafibrate), salicylates, cyclophosphamide, prolonged-release sulfonamides, fluoxetine, fenfluramine, reserpine, anti-tuberculosis drugs (ethionamide), chloramphenicol, pentoxifylline, theophylline, guanethidine, drugs that block tubular ulcers, pyroxiramine drugs containing ethanol, as well as other hypoglycemic agents (biguanides, acarbose, insulin).

The hypoglycemic effect of Diabepharm CF is weakened when combined with barbiturates, glucocorticosteroids, sympathomimetics (epinephrine, clonidine, ritodrin, salbutamol, terbutaline), thiazide diuretics, diazoxide, isoniazid, glucadone, acetazolamide, medication blockers, acetazoamide-blockers, acetazoamitol), morphine, triamterene, asparaginase, baclofen, danazol, rifampicin, lithium salts, thyroid hormones; in high doses - with chlorpromazine, nicotinic acid, estrogens and oral contraceptives containing them.

Other possible interactions:

• drugs that inhibit bone marrow hematopoiesis: the likelihood of myelosuppression increases;
• ethanol: with combined use, a disulfiram-like reaction may occur;
• cardiac glycosides: the risk of ventricular premature beats increases;
• guanethidine, clonidine, β-blockers, reserpine: against the background of combined use, the clinical manifestations of hypoglycemia can be masked.

Analogs

Analogs of Diabeton MV are: Gliclada, Glidiab, Gliclazid MV, Gliclazid-AKOS, Glucostabil, Diabetalong, Golda MV, Diabefarm, Diabeton MV, Diatica, Diabinax, Reklid, Predian, etc.

Terms and conditions of storage

Store in a place protected from light and moisture at temperatures up to 25 ° C. Keep out of the reach of children.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Diabepharm MV

Reviews of Diabetharm CF are few, since the drug is rarely found in pharmacies and, in comparison with analogues, is prescribed less often.

The price of Diapharm MV in pharmacies

The approximate price for Diabefarm MV 30 mg (60 tablets in a package) is 99-135 rubles.

Diabetharm MV: prices in online pharmacies

Drug name Price Pharmacy

Diabefarm MV 30 mg modified release tablets 60 pcs. RUB 95 Buy

Diabefarm MV tablets with modif. release 30mg 60 pcs. RUB 99 Buy

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!